EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Multicenter study on clinical outcomes and poor prognostic factors in patients with Klebsiella pneumoniae bacteremia receiving cefoperazone/sulbactam treatment

Tsung-Ta Chiang, Ming-Hsien Chiang, Hung-Jen Tang, Zhi-Yuan Shi, Mao-Wang Ho, Chia-Hui Chou, Shang-Yi Lin, Po-Liang Lu, Ting-Shu Wu, Shian-Sen Shie, Jien-Wei Liu, Feng-Yee Chang und 3 weitere

European Journal of Clinical Microbiology & Infectious Diseases · 2024

DOI: 10.1007/s10096-024-04892-x ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Clinical Microbiology & Infectious Diseases, 2024. Verfasst von Tsung-Ta Chiang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri- Service General Hospital, National Defense Medical Cente…. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Sulbactam, Klebsiella Infections, Bacteremia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tri-Service General Hospital, National Science and Technology Council, National Defense Medical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Infections caused by Klebsiella pneumoniae are common and result in high mortality rates. In vitro studies demonstrated the potency of cefoperazone/sulbactam (CPZ/SUL) against Klebsiella pneumoniae . However, the clinical efficacy of CPZ/SUL for the treatment of K. pneumoniae bacteremia has not been studied.

Objectives

This study aimed to associate the clinical outcomes of patients with bacteremia with the minimal inhibitory concentrations (MICs) of CPZ/SUL against the causative K. pneumoniae isolates.

Methods

This multicenter, retrospective study was conducted in Taiwan between July 2017 and April 2021. Patients with K. pneumoniae bacteremia treated with CPZ/SUL were enrolled in this study. CPZ/SUL MICs were determined using the agar dilution method. Data on the patients’ clinical outcomes and characteristics were collected and analyzed.

Results

In total, 201 patients were enrolled. Among the causative K. pneumoniae isolates, 180 (89.5%) were susceptible to CPZ/SUL. Most patients ( n = 156, 77.6%) had favorable outcomes. The 30-day mortality rate was 11.9% ( n = 24). Multivariate risk analyses showed that higher APACHE II score (Odds Ratio [OR], 1.14; Confidence Interval [CI], 1.07–1.21; p < 0.001), metastatic tumors (OR, 5.76; CI, 2.31–14.40; p < 0.001), and causative K. pneumoniae CPZ/SUL MICs > 16 µg/ml (OR, 4.30; CI, 1.50–12.27; p = 0.006) were independently associated with unfavorable outcomes.

Conclusion

Patients with K. pneumoniae bacteremia treated with CPZ/SUL at a ratio 1:1 had favorable outcomes when the CPZ/SUL MICs were ≤ 16 µg/ml. Patients with higher APACHE II scores and metastatic tumors had unfavorable outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Klebsiella pneumoniaeSulbactamKlebsiella InfectionsBacteremiaAnti-Bacterial AgentsCefoperazoneMicrobial Sensitivity TestsHumansMaleFemaleRetrospective StudiesAgedMiddle AgedPrognosisTreatment OutcomeTaiwanAged, 80 and overAdult

Stichwörter der Autor:innen

Klebsiella pneumoniaeBacteremiaBreakpointCefoperazoneMinimal inhibitory concentrationOutcomeSulbactam

Substanzen

SulbactamAnti-Bacterial AgentsCefoperazone

Autor:innen und Institutionen

  • Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri- Service General Hospital, National Defense Medical Center, No. 325, Section 2, Cheng-Kung Road, Taipei, 11490, Taiwan.
  • Department of Nutritional Sciences, Fu-Jen Catholic University, New Taipei City, Taiwan.
  • Institute of Biology and Anatomy, National Defense Medical Center, Tipei, Taiwan.
  • Department of Medicine, Chi Mei Medical Center, Tainan, Taiwan.
  • Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
  • Division of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.

Förderung

  • Tri-Service General Hospital
  • National Science and Technology Council
  • National Defense Medical Center

Zitieren

APA

Chiang, T. T., Chiang, M. H., Tang, H. J., Shi, Z. Y., Ho, M. W., Chou, C. H., Lin, S. Y., Lu, P. L., Wu, T. S., Shie, S. S., Liu, J. W., Chang, F. Y., Chuang, Y. C., Wang, F. D., & Yang, Y. S. (2024). Multicenter study on clinical outcomes and poor prognostic factors in patients with Klebsiella pneumoniae bacteremia receiving cefoperazone/sulbactam treatment. European Journal of Clinical Microbiology & Infectious Diseases. https://doi.org/10.1007/s10096-024-04892-x

Vancouver

Chiang TT, Chiang MH, Tang HJ, Shi ZY, Ho MW, Chou CH, et al. Multicenter study on clinical outcomes and poor prognostic factors in patients with Klebsiella pneumoniae bacteremia receiving cefoperazone/sulbactam treatment. European Journal of Clinical Microbiology & Infectious Diseases. 2024. doi:10.1007/s10096-024-04892-x

BibTeX
@article{Chiang2024,
  author = {Chiang, Tsung-Ta and Chiang, Ming-Hsien and Tang, Hung-Jen and Shi, Zhi-Yuan and Ho, Mao-Wang and Chou, Chia-Hui and Lin, Shang-Yi and Lu, Po-Liang and Wu, Ting-Shu and Shie, Shian-Sen and Liu, Jien-Wei and Chang, Feng-Yee and Chuang, Yin-Ching and Wang, Fu-Der and Yang, Ya-Sung},
  title = {Multicenter study on clinical outcomes and poor prognostic factors in patients with Klebsiella pneumoniae bacteremia receiving cefoperazone/sulbactam treatment},
  journal = {European Journal of Clinical Microbiology & Infectious Diseases},
  year = {2024},
  doi = {10.1007/s10096-024-04892-x}
}
Kostenlos starten →